Cost-Effectiveness Analysis of Afatinib Versus Gefitinib in Egfr-Mutated Population with Advanced Non-Small-Cell Lung Cancer in France
Oct 1, 2017, 00:00
10.1016/j.jval.2017.08.236
https://www.valueinhealthjournal.com/article/S1098-3015(17)30570-3/fulltext
Title :
Cost-Effectiveness Analysis of Afatinib Versus Gefitinib in Egfr-Mutated Population with Advanced Non-Small-Cell Lung Cancer in France
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)30570-3&doi=10.1016/j.jval.2017.08.236
First page :
A439
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
215